Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer

被引:10
|
作者
Stanciu, Adina Elena [1 ]
Hurduc, Anca Elena [2 ]
Stanciu, Marcel Marian [3 ]
机构
[1] Inst Oncol Bucharest, Dept Carcinogenesis & Mol Biol, 252 Fundeni, Bucharest 022328, Romania
[2] Inst Oncol Bucharest, Dept Nucl Med, Bucharest, Romania
[3] Univ Politeh Bucharest, Dept Elect Engn Fac, Bucharest, Romania
来源
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION | 2016年 / 76卷 / 08期
关键词
Amino acids; blood pressure; cardiac pumping; oncology; peptides and proteins; thyroid diagnostics and treatment; thyroid hormones; REMNANT ABLATION; HEART-FAILURE; DISEASE; BIOMARKERS; RISK; RECOMMENDATIONS; HYPOTHYROIDISM; RADIOIODINE; CARCINOMA; EVENTS;
D O I
10.1080/00365513.2016.1230883
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: We aimed to investigate the effects of thyroid hormone withdrawal on N-terminal prohormone forms of atrial natriuretic peptide (NT-proANP) and brain natriuretic peptide (NT-proBNP) during radioiodine therapy in female patients with differentiated thyroid cancer (DTC).Methods: Serum concentrations of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), NT-proANP and NT-proBNP were measured in 51 female patients with DTC (48.74.2 years) at three time-points: day of radioiodine therapy (t1 - under acute hypothyroidism), 5 days after radioiodine (t2 - under acute hypothyroidism) and 3 months after radioiodine (t3 - under TSH suppression). Thirty healthy euthyroid women served as controls (42.85.6 years).Results: At t1/t2/t3, median NT-proANP was 5.2/1.7/487pmol/L vs. 297.7pmol/L in control group (p<0.001), median NT-proBNP was 50.1/36.5/79.5pmol/L vs. 64.5pmol/L (p<0.001) and median NT-proANP/NT-proBNP ratios was 0.20/0.18/4.81 vs. 4.14 (p<0.001). In acute hypothyroidism, FT3 levels were positively correlated with NT-proANP (r=0.38, p=0.005), NT-proANP/NT-proBNP ratios (r=0.47, p=0.001), heart rate (r=0.39, p=0.005), and negatively with mean arterial blood pressure (r=-0.58, p<0.001).Conclusions: Our results indicate that NT-proANP reflects more accurately direct thyroid hormone effects than NT-proBNP. Thyroid hormone-dependent hemodynamic effects seem to be overlapped on the direct stimulatory effect of thyroid hormones on NT-proANP secretion by cardiac myocytes.
引用
收藏
页码:626 / 631
页数:6
相关论文
共 50 条
  • [21] The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy
    Lee, Soo Jin
    Lee, Ho-Young
    Lee, Won Woo
    Kim, Sang Eun
    NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (07) : 727 - 732
  • [22] Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer
    Jiang, Yuyan
    Jin, Jiahui
    Fan, Jingzheng
    Huang, Chao
    Jia, Qiang
    Tan, Jian
    He, Xianghui
    Zheng, Xiangqian
    Zhao, Yue
    Zhang, Qing
    Meng, Zhaowei
    Wang, Yan
    BIOMARKERS IN MEDICINE, 2021, 15 (11) : 879 - 890
  • [23] Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer
    Hong C.M.
    Ahn B.-C.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (4) : 247 - 253
  • [24] Comparing therapeutic outcomes: radioactive iodine therapy versus non-radioactive iodine therapy in differentiated thyroid cancer
    Tiuca, Robert Aurelian
    Tiuca, Oana Mirela
    Pop, Raluca Monica
    Pascanu, Ionela Maria
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [25] Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy
    Liu, Wen
    Jiang, Beibei
    Xue, Jingli
    Liu, Ruijing
    Wei, Yuqing
    Li, Peifeng
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 69
  • [26] The efficacy of adjuvant radioactive iodine therapy for patients with recurrent differentiated thyroid carcinoma
    Maskell, David
    Benson, Richard
    Harrison, Inge
    Barnett, Gill
    Jefferies, Sarah
    CLINICAL ONCOLOGY, 2018, 30 : E2 - E3
  • [27] Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
    Lakhdar, Majdouline Bel
    Mouaden, Ayat
    Zekri, Mourad
    Alami, Dounia
    Zarouf, Hamza
    Ghfir, Imad
    Guerrouj, Hasnae
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2024, 23 (03) : 185 - 190
  • [28] Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma
    Ladenson, PW
    Braverman, LE
    Mazzaferri, EL
    BruckerDavis, F
    Cooper, DS
    Garber, JR
    Wondisford, FE
    Davies, TF
    DeGroot, LJ
    Daniels, GH
    Ross, DS
    Weintraub, BD
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13): : 888 - 896
  • [29] Experiences of low iodine diets in the treatment of differentiated thyroid cancer with radioactive iodine ablation therapy
    Herbert, Georgia
    Searle, Aidan
    England, Clare Yvonne
    Ness, Andy
    Beasley, Matthew
    Haupt-Schott, Ingrid
    Moss, Laura
    Wescott, Judith
    Atkinson, Charlotte
    CLINICAL NUTRITION ESPEN, 2020, 39 : 190 - 197
  • [30] Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer
    Coura-Filho, George Barberio
    Willegaignon, Jose
    Buchpiguel, Carlos Alberto
    Sapienza, Marcelo Tatit
    THYROID, 2015, 25 (12) : 1291 - 1296